# Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

> **NCT01134510** · PHASE1,PHASE2 · COMPLETED · sponsor: **Stanley Jordan, MD** · enrollment: 20 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** C1 Esterase Inhibitor
- **DRUG:** Placebos

## Key facts

- **NCT ID:** NCT01134510
- **Lead sponsor:** Stanley Jordan, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2013-11
- **Final completion:** 2013-11
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2017-03-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134510

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134510, "Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01134510. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*